{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:10:40Z","timestamp":1792599040362,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cabotegravir + rilpivirine long\u2010acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV\u20101 treatment in virologically suppressed (viral load [VL] &lt;50 copies\/mI individuals. In clinical trials, CAB+RPV LA was non\u2010inferior to oral antiretroviral therapy (ART) regimens in virologically suppressed individuals. We compared real\u2010world effectiveness between CAB+RPV LA and oral ART regimens and assessed predictors of confirmed virologic failure (CVF) on CAB+RPV LA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From the OPERA\n                      <jats:sup>\u00ae<\/jats:sup>\n                      cohort, ART\u2010experienced, virologically suppressed adults with HIV switching to CAB+RPV LA or a new oral ART regimen between 21 January 2021 and 31 December 2022 were followed through 30 June 2023. CVF was defined as 2 VL \u2265200 copies\/ml or 1 VL \u2265200 copies\/ml + discontinuation. Logistic regression was used to assess CVF risk by regimen and CVF predictors among CAB+RPV LA users.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 1362 virologically suppressed adults switched to CAB+RPV LA, and 2783 switched to a new oral ART regimen (92% second\u2010generation integrase inhibitor [INSTI]\u2010based). Compared to oral ART users, CAB+RPV LA users were younger, on their prior regimen less time and more likely to switch from an INSTI; median CD4 counts at initiation were similar. At study end, 81% of CAB+RPV LA users and 80% of oral ART users were on their respective regimens. CVF risk with CAB+RPV LA did not statistically differ compared to oral ART (adjusted odds ratio: 0.64; 95% confidence interval [CI]: 0.34, 1.14). Among CAB+RPV LA users, only baseline CD4 predicted CVF; every 100 CD4 cells\/\u00b5l increase was associated with 20% lower CVF risk (OR [95% CI]: 0.80 [0.64, 0.97]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the United States, routine clinical care, CVF risk did not differ between a switch to CAB+RPV LA or new oral ART, with most individuals remaining on their regimens at study end. Lower CD4 count at initiation was the only predictor of CVF on CAB+RPV LA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.70068","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:24:43Z","timestamp":1765977883000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparable real\u2010world effectiveness between switches to cabotegravir + rilpivirine long\u2010acting or modern daily oral regimens in the United States: an OPERA cohort study"],"prefix":"10.1002","volume":"28","author":[{"given":"Ricky K.","family":"Hsu","sequence":"first","affiliation":[{"name":"AIDS Healthcare Foundation  New York New York USA"},{"name":"NYU Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Sension","sequence":"additional","affiliation":[{"name":"CAN Community Health  Fort Lauderdale Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quateka","family":"Cochran","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation  Fort Lauderdale Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Levis","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Sridhar","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Van","family":"Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Wohlfeiler","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355"},{"key":"e_1_2_13_3_1","unstructured":"U.S. Food & Drug Administration.FDA approves Cabenuva and Vocabria for the treatment of HIV\u20101 infection.2021. Accessed November 6 2025. Available from:https:\/\/www.fda.gov\/drugs\/human\u2010immunodeficiency\u2010virus\u2010hiv\/fda\u2010approves\u2010cabenuva\u2010and\u2010vocabria\u2010treatment\u2010hiv\u20101\u2010infection."},{"key":"e_1_2_13_4_1","unstructured":"ViiV Healthcare.ViiV Healthcare announces label update for its long\u2010acting HIV treatment Cabenuva (cabotegravir rilpivirine) to be initiated with or without an oral lead\u2010in period.2022. Accessed November 6 2025. Available from:https:\/\/viivhealthcare.com\/en\u2010us\/media\u2010center\/news\/press\u2010releases\/2022\/march\/viiv\u2010healthcare\u2010announces\u2010label\u2010update\u2010for\u2010its\u2010long\u2010acting\u2010hiv\/."},{"key":"e_1_2_13_5_1","volume-title":"Product Monograph for Cabenuva","author":"ViiV Healthcare","year":"2020"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00152-8"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30340-4"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003025"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab439"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_2_13_17_1","unstructured":"RanaAI BaoY ZhengL SieczkarskiS LakeJE FichtenbaumCJ et\u00a0al.Long\u2010acting injectable CAB\/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359. CROI; March 3\u20136 2024."},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2023.0108"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00890-2"},{"key":"e_1_2_13_21_1","unstructured":"NIH.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.2021. Available from:https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv\u2010clinical\u2010guidelines\u2010adult\u2010and\u2010adolescent\u2010arv\/what\u2010start\u2010initial\u2010antiretroviral\u2010specific\u2010clinical\u2010scenarios?view=full. Accessed April 25 2022."},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-025-00769-x"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae171"},{"key":"e_1_2_13_24_1","unstructured":"LackeyPCPWR PieroneJr.G SensionM MillsA WohlfeilerMB FuscoJS et\u00a0al.Increased screening for sexually transmitted infections and HIV surrogate marker testing among long\u2010acting injectable versus daily oral antiretroviral therapy users in the OPERA\u00ae cohort.25th International AIDS Conference;2024July 22\u201326 2024;Munich Germany."}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:54:21Z","timestamp":1769590461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/jia2.70068"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70068","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70068"}}